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OBJECTIVES: Quantitative fluorescence polymerase chain reaction (QF-PCR) is a rapid and reliable method for
screening aneuploidies, but in Brazil, it is not used in public services. We investigated the accuracy of QF-PCR for
the prenatal recognition of common aneuploidies and compared these results with cytogenetic results in our
laboratory.
METHOD: A ChromoQuant QF-PCR kit containing 24 primer pairs targeting loci on chromosomes 21, 13, 18,
X and Y was employed to identify aneuploidies of the referred chromosomes.
RESULTS: A total of 162 amniotic fluid samples analyzed using multiplex QF-PCR were compared with karyotyping
analysis. The QF-PCR results were consistent with the results of cytogenetic analysis in 95.4% of all samples.
CONCLUSION: QF-PCR was demonstrated to be efficient and reliable for prenatal aneuploidy screening. This
study suggests that QF-PCR can be used as a rapid diagnostic method. However, rearrangements and some
mosaic samples cannot be detected with this test; thus, those exceptions must undergo cytogenetic analysis.
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’ INTRODUCTION
The most frequent chromosome abnormality identified in
humans is aneuploidy, which occurs in 5% of all pregnancies
and is the leading cause of pregnancy loss (1). Numerical and
structural chromosome abnormalities are detected in approxi-
mately one in 200 newborns, and these abnormalities are the most
common causes of developmental disabilities and congenital
malformations in humans (2).
In most countries, cytogenetic analysis has become an
important component of prenatal diagnosis. Since the origin
of cytogenetics, karyotyping has been used as a gold standard
test for aneuploidy diagnosis (3,4). The accuracy of this test is
approximately 99%; however, this technique is laborious and
involves a long reporting time because of the necessity for cell
culture (2-5). For most clinical genetics laboratories, the results
can take 10 to 15 days, which is a long waiting period for
anxious parents.
To reduce parent stress and the time for diagnosis, the
demand for rapid diagnostic methods that do not require cell
culture has increased. These tests can detect aneuploidies
using molecular techniques, such as quantitative fluorescent
polymerase chain reaction (QF-PCR) (6). QF-PCR involves
the amplification of small repetitive DNA sequences – short
tandem repeats (STRs) – using fluorescent primers, followed
by quantitative analysis of the products to evaluate the
numbers of copies of specific chromosomes (7). Although a
microsatellite marker is heterozygous, the ratio of its allele
peak areas represents a disomic (1:1) or trisomic (2:1, 1:2, or
1:1:1) chromosome complement. A marker is uninformative
if only a single peak is observed (8).
In 2000, QF-PCR was first introduced to the UK National
Health Service as a validated and efficient diagnostic test (9).
In Stockholm, since 2005, women have been able to choose
between QF-PCR alone or full karyotype for prenatal
diagnosis (10), and in the USA, since 2006, this method has
been validated and available (11). In Brazil, this technique is
not widely available: only a few private services offer either
QF-PCR or fluorescence in situ hybridization (FISH) in associa-
tion with cytogenetic culture; furthermore, none of them are
offered as a routine public service.
The lack of studies involving prenatal diagnosis using
QF-PCR methods in Brazil contributed to this study. The aims
of this study were to investigate the diagnostic test performance
of QF-PCR for the detection of trisomy 13, 18, and 21 and
sex chromosome aneuploidies in high-risk pregnancies, to
compare these results with karyotypes and to introduce this
method as routine practice in our university hospital.DOI: 10.6061/clinics/2017(07)02
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’ MATERIALS AND METHODS
Study samples
The data for this study were derived from the analysis of
stored amniotic fluid obtained during prospective amnio-
centesis for prenatal diagnosis. A total of 162 samples of amniotic
fluid were collected from pregnant women who were referred
to the Obstetric Clinic at the Hospital das Clínicas da Faculdade
de Medicina da Universidade de São Paulo (HC-FMUSP), São
Paulo, Brazil, from August 2009 to May 2013. This study was
approved by the University Ethics Committee (CAPPESq-
0789/08) in accordance with the ethical standards of the respon-
sible committee on human experimentation. All participants in
the study provided written informed consent.
QF-PCR tests were performed by the same person (first
author), and samples were analyzed with the karyotype results
blinded. All women received genetic counseling, and routine
informed consent was obtained in all cases included in the
study. The clinical indications for karyotyping investigation
included increased nuchal translucency (NT) thickness, pre-
vious child with chromosome abnormalities and structural fetal
malformations. Most prenatal samples were collected between
12 and 34 weeks of gestation. At least 20 mL of amniotic fluid
was collected from each pregnant woman, and 1 mL was
allocated for our research and stored at – 80 oC for posterior
analysis. Conventional cytogenetic analyses were performed on
all the prenatal samples, which were cultured according to
standard procedures in the HC-FMUSP, and results were issued
between 14 and 21 days later.
DNA extraction
DNA was extracted from fetal cells, which were obtained
from amniotic fluid (1.0 mL) using a QIAamp DNA Blood
Mini kit (Qiagen, Germany; CITOGEM Biotecnologia Ltda).
Nucleic acids were eluted in a final volume of 65 mL of
elution buffer. After extraction, the quality and quantity of
DNA were evaluated by spectrophotometry on a NanoDrop
2000 (Thermo Fisher Scientific, USA).
Markers used
The assay uses multiplex PCR targeting STR markers to
assess the copy numbers of chromosomes 13, 18, 21, X and Y.
A total of 24 markers were selected for this study: 5 markers
for chromosome 13 (D13S797, D13S742, D13S634, D13S628,
and D13S305), 6 for chromosome 18 (D18S391, D18S976,
D18S819, D18S390, D18S386, and D18S535), 6 for chromo-
some 21 (D21S1409, D21S11, D21S1411, D21S1246, D21S1444,
and D21S1435), 3 for chromosome X (DXS6854, DXS6803,
and XHPRT), 1 STR on the Y chromosome (SRY) and 2 for
regions on the X and Y chromosomes (DXYS218 and X22).
The amelogenin gene (AMXY) and SRY were used to allow
for the assessment of fetal sex. QF-PCR is a quantitative
method: the areas and the heights of the peaks are comparable.
Multiplex QF-PCR
PCR amplification was performed in two reactions using
10 mL of the extracted DNA and 15 mL of ChromoQuant
QF-PCR v.3 (Cybergene AB, Sweden) mix. After initial denatura-
tion at 95 oC for 15 min, 26 cycles of amplification were
performed (denaturation at 94 oC for 30 s, annealing at 57 oC
for 1 min and extension at 71 oC for 2 min) followed by final
extension at 71 oC for 5 min and 60 oC for 1 hour. The reaction
was performed in a thermal cycler (Eppendorf, Germany).
Genescan analysis and reporting
The amplified samples were pooled together (1.0 mL) with
12 mL of Hi-Di formamide (Applied Biosystems, USA) and
0.3 mL of ROX500 (Applied Biosystems, USA). This mixture
was denatured at 95 oC for 3 min, transferred to ice and
left until the sample was loaded on an ABI 3130 Genetic
Analyzer. The samples were run on a POP7 polymer and a
36-cm capillary, and the obtained results were analyzed with
Gene Mapper V4.0 (Softgenetics, USA). For reporting, the
peak height ratio or area ratio was calculated. We considered
a minimum of two markers to be informative for reporting,
following the manufacturer’s protocol. The allele ratio for the
normal range was from 0.8 to 1.4. If the ratio ranged from 1.8
to 2.4 or 0.45 to 0.65, it was considered trisomy positive for
three individual peaks (1:1:1) with respect to each marker
considered trisomy positive.
Cytogenetic analysis
Amniocytes were cultured and G banding was performed
for all cases. These samples were analyzed at the cytogenetic
laboratory at the Hospital das Clínicas da Universidade de
São Paulo. Routine evaluation of each case involved the analysis
of 20 random metaphase spreads from two independent cul-
tures. Karyotypes were described according to the International
System for Human Cytogenetic Nomenclature (ISCN2013).
Statistical analysis
To determine appropriate sample size, a power calculation
using a sensitivity of 83.73% was performed as described by
Rostami et al. (12) in a group of pregnant women selected for
karyotype studies according to increased maternal age and
positive screen test; the prevalence of an abnormal karyotype
was 4%. Considering that 55% of the samples in the present
study presented abnormal karyotypes with a maximum
estimated error of 10%, the 95% confidence interval would be
achieved in a sample size of 95 cases.
’ RESULTS
Patient demographics
The samples obtained from the Brazilian population included
105 white volunteers, 45 brown volunteers, 9 black volunteers
and 2 indigenous volunteers; 1 was unknown. Classifications of
ethnicity were made according to the self-assessment of the
volunteers.
The mean maternal age was 29 years old (range, 14-49
years); 55 women (33.95%) were 35 years of age or older. The
median gestational age of amniocentesis was 23 weeks
(range: 11 weeks to 34 weeks).
The results of 162 QF-PCR samples were compared to
results obtained by culture conventional cytogenetic analy-
sis, as presented in Table 1. There were two false-positives
and one false-negative. The false-negative QF-PCR result
was observed in one mosaicism for Turner syndrome; this
sample was analyzed and reported as a normal female fetus.
False-positives were found in 2 cases: one normal male
with trisomy 18 and one normal female with polyploidy
metaphases that showed abnormal results for chromosomes
21, 18, 13 and X. There were 151 samples corresponding with
cytogenetic results (98.05%), excluding cases with chromo-
somal rearrangement. Table 2 shows the sensitivity, specifi-
city, and positive and negative predictive values for all
cases excluding those with rearrangements and mosaicism.
The number and percentage of aneuploidies detected in
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fetuses were compared with different ages of the mothers,
as shown in Table 3.
Among the discrepant results, 8 were due to chromosomal
rearrangements, including one addition (46, XX, +add (7)
(q33)), two translocations (46, XX,+13 rob (13, 14) (q10q10),
46, Y, t (X,14) (q22q31)), three inversions (46, XX,+i (1) (q10),
46, XY inv (9), 46, XY, inv (9) (p12q13)), one deletion (46, XX,
del (11) (q22)), and one duplication (46, XY, dup (3)
(p21.2p25)). In five cases of mosaicism, QF-PCR identified
four abnormal trisomy karyotypes of the corresponding
chromosomes (Table 4).
Analysis of the heterozygosities of STR markers
The heterozygosities of selected markers for QF-PCR are
shown in Table 5. The markers D21S1435, D21S1409, and
D21S1246 more commonly showed in a triallelic pattern,
whereas the markers D13S742, D21S11, and D18S386 showed
a diallelic pattern. For the sex chromosomes, the marker X22
had the highest frequency of heterozygosity.
’ DISCUSSION
In recent years, QF-PCR for the detection of common chro-
mosomal trisomies has been introduced as a validated method
at a number of cytogenetic centers (13-16). Our study presents
results based on the application of QF-PCR for the rapid
detection of aneuploidies in chromosomes 13, 18, 21, X and Y
on 162 amniotic fluid samples in the Brazilian population.
The QF-PCR results alone were in accordance with 98.05%
of all karyotypes excluding cases with chromosomal rear-
rangements. These results are compatible with other recent
reports in the literature. Lildballe et al. (17) analyzed 2,550
samples from chorionic villus sampling (CVS) and amniotic
fluid from high-risk pregnancies and reported positive and
negative predictive values greater than 99.8%. In this work,
different predictive values were reported for each chromo-
somal abnormality, and even for mosaic trisomies, the detection
Table 1 - Comparison of QF-PCR and conventional cytogenesis
results in AF samples.
Karyotype Cytogenetic, N (%) QF-PCR, N (%)
46, XX; 46, XY 72 (44) 70 (43)
47, XX +21; 47, XY +21 28 (17) 28 (17)
47, XX +18; 47, XY +18 21 (13) 21 (13)
47, XX +13; 47, XY +13 9 (6) 9 (6)
Turner syndrome (45, X) 17 (10) 17 (10)
Triploidy (69, XXX; 69, XXY) 2 (1) 2 (1)
Mosaics 5 (3) 4 (2)
Rearrangements 8 (5) 0 (0)
Total abnormalities 90 (56) 81 (50)
Test accuracy (%) 100 93
Table 4 - Discrepant cases of QF-PCR.
Rearrangements QF-PCR
46, XX, +add (7) (q33) 46, XX
46, XX, +13 rob (13, 14) (q10q10) 46, XX
46, Y, t (X,14) (q22q31) 46, XY
46, XX, +i (1) (q10) 46, XX
46, XY inv (9) 46, XY
46, XY, inv (9) (p12q13) 46, XY
46, XX, del (11) (q22) 46, XX
46, XY, dup (3)(p21.2p25) 46, XY
Mosaics QF-PCR
45, X0 / 46, XX, +mar 46, XX
46, XY / 47, XY, +18 47, XY, +18
46, XY / 47, XY, +18 47, XY, +18
47, XX, +13 / 48, XX, +13 mar 47, XX, +13
47, XX, +mar / 47, XX, +13 47, XX, +13
Table 3 - Number and percentage of aneuploidies in fetuses detected using QF-PCR as stratified by the mother’s age.
Mother’s age Total Aneuploidies N (%) 47, XX/XY +21 47, XX/XY +18 47, XX/XY +13 45, X 69, XXX, 69, XXY
o35 48 (63) 13 (17) 14 (18) 7 (9) 12 (16) 2 (3)
X35 29 (37) 15 (19) 7 (9) 2 (3) 5 (6) 0 (0)
Total 77 (100) 28 (36) 21 (27) 9 (12) 17 (22) 2 (3)
Table 2 - Statistical analysis of AF samples tested using QF-PCR in
high-risk pregnancies with an aneuploid fetus.
Statistical analysis AF samples
without
rearrangements
cases (n=154) (%)
AF samples
without mosaicism
cases (n=157) (%)
Sensitivity 98.78 90.59
Specificity 97.22 97.22
Positive predictive value 97.59 97.44
Negative predictive value 98.59 89.74
Accuracy 98.05 93.63
Table 5 - QF-PCR results for each STR marker of chromosomes
13, 18, 21, X and Y.
STR Chromosome
location
Mono allelic,
N (%)
Diallelic,
N (%)
Triallelic,
N (%)
AMEL Xp22.31 – Xp22.1
Yp11.2
93 (58) 66 (41) 2 (1)
DXYS218 Xp22.32 / Yp11.3 67 (41) 91 (56) 4 (2)
DXS6803 Xq21.31 100 (62) 58 (36) 3 (2)
DXS6854 Xq26.1 107 (66) 52 (32) 3 (2)
XHPRT Xq26.1 97 (60) 63 (39) 2 (1)
X22 Xq28Yq 38 (66) 10 (17) 10 (17)
D21S11 21q21.1 26 (44) 11 (19) 22 (37)
D21S1246 21q22.2 40 (25) 97 (60) 25 (15)
D21S1409 21q21.2 48 (30) 86 (53) 27 (17)
D21S1411 21q22.3 25 (42) 11 (19) 23 (39)
D21S1435 21q21.1 36 (23) 96 (60) 28 (18)
D21S1444 21q22.13 33 (49) 10 (15) 25 (37)
D18S386 18q22.1 22 (37) 11 (19) 26 (44)
D18S390 18q22.3-18q23 72 (44) 80 (49) 10 (6)
D18S391 18p11.31 39 (58) 10 (15) 18 (27)
D18S535 18q12.3 31 (53) 10 (17) 18 (31)
D18S819 18q11.2 39 (60) 10 (15) 16 (25)
D18S976 18p11.31 41 (57) 10 (14) 21 (29)
D13S305 13q13.3 57 (38) 80 (54) 12 (8)
D13S628 13q31.1 45 (71) 10 (16) 8 (13)
D13S634 13q21.33 50 (32) 96 (61) 12 (8)
D13S742 13q12.13 14 (35) 13 (33) 13 (33)
D13S797 13q33.2 36 (60) 11 (18) 13 (22)
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rate was higher than 99.8%. Rostami et al. (12) reported 4,058
samples analyzed for QR-PCR with a detection rate of 98.59%.
Tekcan et al. (18) compared 100 amniotic fluid samples
with karyotype results and obtained 99% concordance on
100 samples, including 4 abnormalities. These three authors
reported higher detection rates than in our study; however, the
percentages of total chromosomal abnormalities in these studies
were 7.6% and 4.1%, respectively, whereas in the current study,
approximately half of the population was abnormal. This
difference in the prevalence of aneuploidy could be explained
by the indication of the karyotype that was primarily due to
fetal malformation in our study.̌
̌
L/aczman´ńska et al. (19) analyzed
100 samples of amniotic fluid and obtained compatibility in
95 cases (95%), which agrees with our study due to the higher
number of chromosomal abnormalities, which were found in
28 pregnancies (29.5%).
Our detection rate of 98.8% included five cases of mosa-
icisms; among which four of these samples returned abnormal
QF-PCR results, which was in agreement with the chromo-
some involved in the abnormality. If we consider that an
abnormal result should be further confirmed by cytogenetic
analysis, these four cases could be considered positive screen
tests for aneuploidy in QF-PCR. Additionally, one Turner
mosaic sample was revealed to be normal in QF-PCR testing.
This result is in accordance with the literature and can be
explained by lower rates of mosaic cells (less than 15%) (19-22).
Of the two false-positive results, one revealed a triploid
female upon QF-PCR with a normal polyploidy meta-
phases karyotype upon cytogenetic analysis. These poly-
ploidy metaphases might be the reason for the false-positive
result, though its significance is unknown. A second false-
positive was a normal male, which was revealed as trisomy
18. The sample was bloodstained, so this false result might
be explained by maternal contamination.
The markers D21S1435, D13S742, D13S797, and D18S1386
were the most frequently informative in all cases of trisomies
21, 13 and 18, respectively, in our population, displaying a
higher frequency of heterozygosity.
QF-PCR is a rapid, robust and accurate diagnostic method
for detecting common aneuploidies in high-risk pregnancies,
with results available in two days because fetal cells do not
have to be cultured.
The Implementation of QF-PCR at a public referral center
or laboratory could improve patient care and reduce over-
all health costs. A strategy could be proposed in which, in
combination with traditional 1st trimester screening tests,
pregnant women could be referred for karyotyping via
QF-PCR due to advanced maternal age, anxiety, NTo3 mm
or a high-risk for trisomies; this would eliminate the need for
karyotyping by culture. Karyotyping still should be applied
in pregnancies with normal QF-PCR results and the presence
of either structural abnormalities detected by ultrasound or
two or more soft markers for Down syndrome as well as a
family history of chromosome rearrangement.
This approach has been implemented in London and has
led to a 99.9% detection rate of any chromosomal abnorm-
ality, which has reduced the need for a full karyotype
analysis to only 25% of pregnancies (23). For the public
health system in Brazil, where most pregnant women do not
have access to fetal karyotyping, an initial investigation with
a rapid and feasible assay such as QF-PCR would provide
the opportunity to offer tests at a central laboratory and
include more patients. Although QF-PCR cannot detect all
chromosomal abnormalities, this assay can cover more than
97% of the predicted chromosomal anomalies when a fetal
karyotype is requested.
As for any other prenatal test, employing this assessment
requires investment in infrastructure, equipment and train-
ing for the lab staff. This test can decrease the demand for
conventional cytogenetic analysis and can reduce parental
anxiety as well as expand the reach of this test throughout
the population.
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